A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

NCT03076164 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Lung Adenocarcinoma
Lung Cancer
Lung Cancer Metastatic
Lung Cancer Stage IV
Recurrent Lung Adenocarcinoma
Recurrent Lung Cancer

Interventions

DRUG: Trametinib
DRUG: Erlotinib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]